Predict your next investment

Cernostics company logo
HEALTHCARE | Medical Devices & Equipment
cernostics.com

See what CB Insights has to offer

Stage

Unattributed - II | Alive

Total Raised

$21.34M

Last Raised

$5.98M | 2 mos ago

About Cernostics

Cernostics is a diagnostics company focused on delivering next generation cancer diagnostics and prognostics through a unique approach to tissue analysis. Cernostics takes a tissue systems biology approach to anatomic pathology. Its patent-protected technology platform, TissueCypher, uniquely analyzes whole slide digital images with multiplexed fluorescence, providing greater information and accuracy than traditional subjective tissue diagnostics. Learn more about our technology platform and how it will change the future of cancer diagnostics.

Cernostics Headquarter Location

235 William Pitt Way

Pittsburgh, Pennsylvania, 15238,

United States

412-828-0900

Latest Cernostics News

Cernostics Announces Blinded, Independent Validation of TissueCypher(R) Performance for Predicting Risk of Progression to Esophageal Cancer in Patients With Non-Dysplastic BE

Jun 25, 2020

Study further validates TissueCypher(R) as the first and only precision medicine test proven to provide actionable data for predicting patient progression to high-grade dysplasia and esophageal adenocarcinoma News provided by Share this article PITTSBURGH, June 25, 2020 /PRNewswire/ -- Cernostics, a leader in the development of AI-driven image analysis technologies for precision medicine testing, today announced publication of new clinical results demonstrating further validation of how its TissueCypher(R) diagnostic test predicts future disease progression in patients with Barrett's Esophagus (BE). (Abstract available here . Full article available via journal subscription.) By identifying "at-risk" patients much earlier than traditional methods, TissueCypher provides actionable results that allow physicians to target early therapeutic interventions to prevent cancer. TissueCypher detected multiple high-risk features in this biopsy from a patient with short segment, non-dysplastic Barrett's esophagus, as confirmed by the GI subspecialist. TissueCypher scored this case High Risk for progression to HGD/EAC within five years. The patient was diagnosed with HGD on surveillance endoscopy 2.5 years later. TissueCypher is the first and only precision medicine test designed, developed, and commercialized to predict which patients with Barrett's Esophagus will progress to high-grade dysplasia (HGD) or esophageal adenocarcinoma (EAC). In this study, funded by the NIH/NCI, patients with BE who progressed to HGD or EAC after at least one year following endoscopy (n=58) were matched to patients with BE without disease progression after a median of seven years surveillance (n=210). Results demonstrated that patients classified as high-risk by TissueCypher® were at 4.7-fold increased risk for HGD/EAC compared to those classified as low-risk (p<0.0001). Furthermore, this study demonstrated that patients with non-dysplastic BE who TissueCypher scored high-risk progressed to HGD or EAC at a rate of more than 5%/year, which is at least a 10-fold increase in reported progression rates for NDBE, based on large population studies. In an editorial accompanying the published results, Prasad G. Iyer, MD, MSc, at Mayo Clinic in Rochester, Minnesota, describes TissueCypher as the potential "Holy Grail" for Barrett's Esophagus. "Identification of those at higher risk may allow either intensive endoscopic surveillance (to detect incident dysplasia/EAC) or proactive EET, whereas surveillance intervals could be lengthened in those at low risk. This risk prediction has been referred to as the 'Holy Grail' in BE." "This is the third independent study showing that TissueCypher gives physicians crucial predictive power beyond expert diagnosis, especially in that difficult subset of patients whose true risk may go unnoticed if we rely solely on traditional methods," said lead author Jon M. Davison, MD, Associate Professor of Pathology at University of Pittsburgh in Pittsburgh, Pennsylvania. TissueCypher's unique advantages stem from its patented, AI-based digital platform with multi-channel fluorescence imaging that provides physicians with a more in-depth, accurate, and comprehensive view of each patient's unique pathology. "The TissueCypher image analysis platform simultaneously and objectively extracts protein expression information from multiple biomarkers, as well as provides a digital expression of tissue architecture and nuclear morphology," says Vani J.A. Konda, MD, Clinical Director, Center for Esophageal Diseases, at Baylor University Medical Center in Dallas, Texas, and a key opinion leader in the use of imaging and novel screening techniques to improve early detection and treatment. "The information physicians receive is meaningful, accurate, and immediately actionable." Dr. Konda has published extensively on the role of biomarkers for improving risk stratification in patients with Barrett's Esophagus, including an upcoming review paper in the July 2020 issue of Gastroenterology & Endoscopy News. Cernostics' innovative technology is unique in today's market because tissue structure is preserved while immune, stromal, stem cell and tumor biomarkers are analyzed – all of which is done by evaluation of standard esophageal pinch biopsies readily available from the endoscopy procedure. Biomarker intensity and spatial relationships within the tissue structure are also analyzed and reported, creating an in-depth picture of the patient's risk from which the physician can create successful patient management protocols. TissueCypher has been tested and validated in five independent clinical studies at leading centers around the world, including Cleveland Clinic, University of Pennsylvania Medical Center, Geisinger Health, and Academic Medical Center in Amsterdam. Most recent peer-reviewed results are published currently in the June 2020 issue of the American Journal of Gastroenterology. Using a pinch biopsy specimen routinely collected by the gastroenterologist during an endoscopy procedure, TissueCypher is easily incorporated into a physician's current practice. The test requires no additional tools or collection devices, as are needed with other currently available diagnostic options. About Barrett's Esophagus Barrett's Esophagus (BE) affects more than three million Americans, occurring when chronic exposure to stomach acid causes the esophageal cell lining to deteriorate and undergo changes that can create an environment for cancer. Without treatment, Barrett's can lead to EC, with a poor five-year survival of less than 20%. Today, Barrett's is commonly managed by surveillance, involving regular endoscopic procedures with biopsy, monitoring disease progression, and GERD-related drug therapy to control symptoms and prevent esophageal injury. About Cernostics Cernostics, a leader in tissue-based diagnostic testing, provides diagnostic tests with deeper tissue insights, better patient outcomes, and lower cost of care. Cernostics' mission is to quantify the tissue system complexity, providing physicians and patients with individualized, actionable information to improve outcomes and reduce the incidence and mortality of cancer. For a complete listing of Cernostics' published patents, visit  www.cernostics.com/IP . Media Contact:

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Cernostics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Cernostics is included in 3 Expert Collections, including Medical Devices.

M

Medical Devices

7,438 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. Excludes CDMOs/CMOs. *Columns updated as regularly as possible.

C

Cancer

3,604 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

D

Digital Health

10,319 items

Companies using/incorporating digital tech into health, wellness, and life science offerings. Includes cos operating within the hc, consumer health, and life science industries + tech vendors catering to them. Excludes cos exclusively focused on fitness/sports & performance

Cernostics Patents

Cernostics has filed 6 patents.

The 3 most popular patent topics include:

  • Esophagus disorders
  • Molecular biology
  • Anatomical pathology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

11/23/2016

3/30/2021

Oncology, Esophagus disorders, Anatomical pathology, Rare diseases, Molecular biology

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

11/23/2016

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

3/30/2021

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Oncology, Esophagus disorders, Anatomical pathology, Rare diseases, Molecular biology

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Cernostics Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Cernostics Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.